Volume 6.09 | Mar 13

Cord Blood News 6.09 March 13, 2014
Cord Blood News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Long-Lasting HHV-6 Reactivation in Long-Term Adult Survivors after Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation
Higher incidence of HHV-6 infection has been documented after umbilical cord blood allo-transplant in adults. Here, researchers demonstrated that HHV-6 reactivation persists for a very long time in half of the patients after this type of graft. [J Infect Dis] Abstract
FREE Technical Resource: Atlas of Hematopoietic Colonies from Cord Blood. Request your copy.
PUBLICATIONS (Ranked by impact factor of the journal)
Reduced Intensity Conditioning, Combined Transplantation of Haploidentical Hematopoietic Stem Cells and Mesenchymal Stem Cells in Patients with Severe Aplastic Anemia
Investigators examined if transplantation of combined haploidentical hematopoietic stem cells and mesenchymal stem cells (MSC) affected graft failure and graft-versus-host disease in patients with severe aplastic anemia. Stem cell grafts used a combination of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow and G-CSF-mobilized peripheral blood stem cells of haploidentical donors and the culture-expanded third-party donor-derived umbilical cord MSCs, respectively. [PLoS One] Full Article

Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rγnull Mice
Investigators developed a pre-clinical model of human islet transplantation by reconstituting NOD-scid IL2rγnull mice with cord blood-derived human CD34+ stem cells and demonstrated that although the engrafted human immune system mediated the rejection of human islets, their survival was significantly prolonged following adoptive transfer of ex vivo expanded human regulatory T cells. [PLoS One] Full Article

Long-Term Outcome and Prognostic Factors of Unrelated Cord Blood Transplantation in Children with Hematological Malignancies: A Retrospective Study Using the Spanish Working Party for BMT in Children (GETMON) Database
Outcomes of unrelated cord blood transplants were assessed in 172 consecutive children, median age 5 years (range: 0.5-18), with hematological malignancies treated at nine Spanish hospitals between February 1996 and April 2009. [Bone Marrow Transplant] Abstract

Generation of Tunable Glycosaminoglycan Hydrogels to Mimic Extracellular Matrices
Scientists present a novel methodology for the extraction, purification and separation of glycosaminoglycans from umbilical cord obtained from two different species, human and pig. [J Tissue Eng Regen Med] Abstract

Hierarchical Maturation of Innate Immune Defences in Very Preterm Neonates
Using standardized protocols, researchers assayed multiple inflammatory cytokine responses to three prototypic Toll-like receptor (TLR) agonists, i.e. TLR4 (lipopolysaccharide), TLR5 (flagellin) and TLR7/8 (R848), and to the non-TLR retinoic acid-inducible gene I-like receptor agonist, in cord blood mononuclear cells from neonates born before 33 weeks of gestation and at term. [Neonatology] Abstract

Intrathecal Injection of Human Umbilical Cord Blood Stem Cells Attenuates Spinal Cord Ischemic Compromise in Rats
Researchers evaluated the use of human umbilical cord blood stem cells to attenuate the neurological effects of spinal cord ischemia induced by high thoracic aorta occlusion. [Interact Cardiovasc Thorac Surg] Full Article

NEW STEMvision CB, BM & MPB Algorithms
Next-Generation Cell Therapies to Prevent Infections in Neutropenic Patients
Neutrophil-like cells can be manufactured in the laboratory at the clinical scale from hematopoietic stem and progenitor cells enriched from umbilical cord blood. This article reviews the rationale for focusing research efforts toward ex vivo neutrophil production and explores clinical settings for future trials. [Stem Cells Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Attend ISCT 2014 in Paris, France!
Preclinical Results for Pluristem’s PLX-PAD Cells in Tendon Injury
Pluristem Therapeutics, Inc. announced that Dr. Scott Rodeo of New York’s Hospital for Special Surgery presented his research findings in a scientific poster titled, “Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury.” [Press release from Pluristem Therapeutics, Inc. discussing research presented at the American Academy of Orthopedic Surgeons’ (AAOS) Annual Meeting, New Orleans] Abstract

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
Fate Therapeutics Commences Phase II Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
Fate Therapeutics, Inc. announced the enrollment of the first patient in its “PUMA” (PROHEMA® in Umbilical cord blood transplant in Adults) study, a Phase II clinical trial of PROHEMA® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) using the Company’s nutrient-rich media formulation. [Fate Therapeutics, Inc.] Press Release

STEMSOFT Announces Release of New BMT Clinic Software Solution
STEMSOFT™ Software Inc. announced the release of a new BMT cellular therapy transplant software solution, STEMSOFT CLINIC. This new system efficiently manages all patient and donor information in one location complete with an available BMT registry submission and retrieval process for all available forms using the CIBMTR AGNIS system. [STEMSOFT™ Software Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Transtem Patient 2014
March 19, 11:00 AM (CDT in US)

NEW Society for Developmental Biology (SDB) 73rd Annual Meeting
July 17-21, 2014
Seattle, United States

NEW Fraunhofer Life Science Symposium: Medicinal Stem Cell Products
October 9-14, 2014
Leipzig, Germany

Visit our events page to see a complete list of events in the cord blood community.
NEW Cell Therapy Lab Technologist II (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

PhD Studentship – Stem Cell Research (University Medical Center Ulm)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Positions – Hematopoietic Stem Cell Physiology and Bone Marrow Failure (University of Michigan)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us